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Abstract 57 
Purpose: The Singapore regulatory agency for health products (Health Sciences Authority), in 58 
carrying out active surveillance of medicines and their potential harms, is open to new 59 
methods to achieve this goal. Laboratory tests are a potential source of data for this purpose. 60 
We have examined the performance of the Comparison on Extreme Laboratory Tests (CERT) 61 
algorithm, developed by Ajou University, Korea, as a potential tool for adverse drug reaction 62 
(ADR) detection based on the electronic medical records (EMR) of the Singapore healthcare 63 
system.   64 
Methods: We implemented the original CERT algorithm, comparing extreme laboratory 65 
results pre- and post-drug exposure, and five variations thereof using 4.5 years of National 66 
University Hospital (NUH) EMR data (31,869,588 laboratory tests, 6,699,591 drug dispensings 67 
from 272,328 hospitalizations). We investigated six drugs from the original CERT paper and 68 
an additional 47 drugs. We benchmarked results against a reference standard we created 69 
from UpToDate® 2015. 70 
Results: The original CERT algorithm applied to all 53 drugs and 44 laboratory abnormalities 71 
yielded a PPV and sensitivity of 50.3% and 54.1%, respectively. By raising the minimum 72 
number of cases for each drug-laboratory abnormality pair from 2 to 400, the PPV and 73 
sensitivity increased to 53.9% and 67.2%, respectively.  This post-hoc variation, named 74 
CERT400, performed particularly well for drug-induced hepatic and renal toxicities.   75 
Discussion: We have demonstrated that the CERT algorithm can be applied across national 76 
boundaries. One modification (CERT400) was able to identify ADR signals from laboratory 77 
data with reasonable PPV and sensitivity, which indicates potential utility as a supplementary 78 
pharmacovigilance tool.   79 
  80 
Text 81 
INTRODUCTION 82 
Traditionally, spontaneous reporting systems (SRS) have been the predominant data source 83 
for the detection of signals of adverse reactions.1-3 This system, usually maintained by a 84 
government agency, receives suspected adverse drug reaction (ADR) reports submitted by 85 
healthcare professionals, pharmaceutical companies and consumers.1-3  With the expanding 86 
use of electronic medical records (EMRs) in recent years, the pharmacovigilance community 87 
has another potentially rich source of information for drug safety surveillance.1,3  The prospect 88 
of scanning EMRs is attractive, as it overcomes some of the limitations inherent in the SRS: (1) 89 
reliance mainly on voluntary reporting from its contributors, and susceptibility to under-90 
reporting as well as over-reporting (e.g. due to media interest), (2) incomplete or missing data, 91 
hindering causality assessment, and (3) difficulty in detecting duplicate reports.1, 2  92 
As EMRs are used for the clinical management of patients, they constitute an information-93 
rich database3 of patients’ demographics, medications, past medical history, laboratory 94 
results, etc, which are commonly missing from ADR reports. The records reflect actual clinical 95 
practice, allowing for a more complete benefit-risk assessment. For specific ADRs, mining of 96 
EMRs has the added advantage of applying a consistent phenotype definition, thus 97 
overcoming variations in diagnostic criteria by different clinicians. However, unlike in SRS 98 
where a clinician has made a connection between the drug and an adverse event and files a 99 
report in a standardized format, much of EMR data are unstructured and housed in different 100 
databases. Pre-processing and data cleaning are required to extract and collate critical 101 
elements, such as drug exposure, concomitant medications, laboratory results, temporal 102 
relationships, and possible confounders.1  103 
The Comparison of Extreme Laboratory Test (CERT) algorithm was developed by Korean 104 
researchers who applied it to 10 different drugs over 10 years of EMR data from Ajou 105 
University Hospital.4  For each patient exposed to a particular drug, the algorithm selects the 106 
extreme laboratory test result (minimum or maximum) among multiple laboratory values 107 
from each of the pre-drug and post-drug exposure periods. CERT then determines whether a 108 
cohort of exposed patients demonstrates a significant change in abnormal laboratory values 109 
after drug exposure. As a regulatory agency seeking to build a toolkit of methods for active 110 
surveillance, the Health Sciences Authority (HSA), Singapore, sought to investigate the 111 
potential applicability of the CERT algorithm on the EMR in the Singapore healthcare system. 112 
The CERT algorithm had many desirable features that we were seeking, namely a temporal 113 
relation between drug exposure and a laboratory abnormality, the flexibility to evaluate any 114 
drug and laboratory test, and good performance metrics. Utilisation of numerical laboratory 115 
values before and after drug exposure made it potentially more portable across national 116 
boundaries, regardless of the language of the country.  The objectives of this work were to 117 
implement and test CERT on the EMRs of the National University of Hospital (NUH), examine 118 
variations that could improve predictive performance, and assess its potential utility as a 119 
pharmacovigilance tool.  120 
 121 
METHODS 122 
Data source 123 
De-identified EMRs were obtained from NUH, a 1,230-bed tertiary hospital, following 124 
approval of the study by the National Healthcare Group Domain Specific Review Board.  The 125 
information retrieved included patient demographics, admission and discharge dates, 126 
inpatient drug dispensings, and laboratory test results over a 4.5 year period from July 2009 127 
to Dec 2013. The data comprised over 31 million (31,869,588) laboratory tests and 6 million 128 
(6,699,591) inpatient drug dispensed orders from 272,327 hospitalization visits for 158,096 129 
patients.  130 
 131 
Selection of drugs for evaluation 132 
Among the ten drugs analysed in the original CERT paper, one drug (ketorolac) was not used 133 
at NUH, while three oncologic drugs (etoposide, fluorouracil and methotrexate) were 134 
incompletely captured because oncologic drugs are mainly ordered and recorded in another 135 
database.  In order to have a direct head-to-head comparison of algorithm performance from 136 
the EMRs of two different healthcare institutions, we first analysed only six drugs described 137 
in the original CERT publication (Round 1, Table 1). 138 
In Round 2, we investigated an additional 47 drugs (Table 2). Factors considered in drug 139 
selection were drug usage volume and the likelihood of the drug being started during 140 
hospitalisation. Drugs with high usage were prioritised to provide sufficient number of cases 141 
for analysis. We also included negative controls (chlorpheniramine, metronidazole and 142 
risedronic acid) with no ADRs detectable by abnormal laboratory test results in the reference 143 
standard.  144 
The CERT algorithm and variations 145 
The original CERT algorithm paper examined 41 laboratory tests and 51 laboratory 146 
abnormalities. Six laboratory tests and seven laboratory abnormalities were not included in 147 
our evaluation because the laboratory results were infrequently ordered by clinicians in NUH 148 
(most of the 53 drugs had zero cases).  Consequently, our evaluation included 35 laboratory 149 
tests and 44 laboratory abnormalities (Supplementary Table S1). 150 
A common issue in assessing EMR data mining is the need for a benchmark reference standard 151 
to evaluate algorithm performance. 1,4  The original CERT publication used the 2010 version of 152 
UpToDate® Drug Information Database (UpToDate Inc, Waltham, MA, USA) to create a 153 
reference standard.  We used the 2010 version of UpToDate® to directly compare our results 154 
with those previously published.  To evaluate the performance of the original CERT algorithm 155 
and variations for all 53 drugs, two pharmacists constructed an updated reference standard 156 
from UpToDate® 2015 (Supplementary Table S3).  As CERT utilises laboratory abnormalities 157 
as a surrogate of ADRs, the ADRs were mapped to their respective laboratory abnormalities 158 
using the mapping table described in the original CERT paper.4  159 
In the original CERT algorithm, a case is defined when (1) the patient was prescribed the study 160 
drug at least once, and (2) at least one laboratory test result exists in each of the pre-drug and 161 
post-drug periods.  A minimum of two cases was required for CERT to run the statistical tests 162 
and generate output. If either the paired t-test or McNemar’s test had P<0.05, the drug-163 
laboratory-abnormality pair would be considered a positive signal. 164 
Four variations of the original CERT algorithm were assessed on the set of 53 drugs (Table 3): 165 
(1) Limiting the period of observation to a defined period after the start of drug exposure, (2) 166 
Limiting the post-drug exposure observation period to a defined number of laboratory tests, 167 
(3) Taking an average of the two most extreme values instead of using only one extreme pre- 168 
and post-drug value, and (4) Using the paired t-test and non-parametric Wilcoxon’s signed-169 
rank test instead of paired t-test and McNemar’s test. A fifth variation was also assessed post-170 
hoc in which only drug-AE pairs with a minimum of 400 cases were included. The rationale for 171 
these variations is presented in the Discussion section. 172 
Evaluation metrics 173 
To evaluate the performance of CERT, we compared the drug-laboratory-abnormality pairs 174 
detected as significant signals by CERT with those identified in the reference standard. We 175 
then calculated the average positive predictive value (PPV), negative predictive value (NPV), 176 
sensitivity and specificity for each drug based on laboratory abnormalities. The F-score, which 177 
is the harmonic mean of PPV and sensitivity, is also reported (Supplementary Table S2). To 178 
contrast the results from different variations of the algorithm and get a pooled point estimate 179 
of the performance metrics and the 95% confidence interval, a random effects meta-analysis 180 
was performed to summarise a particular measurement of interest.  181 
Creation of a reference standard  182 
Supplementary Table S3 presents the reference standard created by mapping ADRs in 183 
UpToDate® 2015 for the 53 drugs to laboratory abnormalities. Researchers may find this a 184 
useful resource for benchmarking other algorithms intended to identify ADRs from laboratory 185 
abnormalities.  However, it is worthwhile to note that this reference standard is not a list of 186 
confirmed ADRs, and is constantly being updated, and hence some may consider it a “silver 187 
standard” rather than a “gold standard”. While UpToDate® contains information from 188 
multiple sources about a drug’s safety profile, ADRs that occur in specific population could be 189 
overlooked, and it may be incomplete for drugs that have only been recently approved.     190 
RESULTS 191 
Evaluation of CERT performance 192 
The PPV, NPV, sensitivity and specificity for Round 1 (6 drugs) are summarised in Table 4A. 193 
When comparing the same drugs between NUH and Ajou University, our results showed 194 
similar PPV (55.6% vs 58%) and better specificity (64.3% vs 52.2%).  We had lower NPV (56.2% 195 
vs 66.7%) and sensitivity (48.9% vs 71.3%). 196 
When the CERT algorithm was evaluated on a larger set of 47 drugs (Round 2) and 197 
benchmarked against an updated reference standard, PPV decreased to 48.5%, specificity was 198 
similar (65.2%), and sensitivity increased to 54.7%.  Combining all 53 drugs evaluated in both 199 
Rounds, overall PPV was 50.3%, specificity was 65.4%, and sensitivity was 54.1% for an F-score 200 
of 52.1% (Table 4B). 201 
Performance across different laboratory panels  202 
Consistent with Ajou University’s findings, the majority of the signals (93.6%) detected by 203 
CERT were from “haematopoiesis and coagulation”, “hepatobiliary enzymes” and “renal 204 
function and urine tests”, and these panels were associated with higher F-scores compared 205 
to the remaining laboratory panels. However, decreases in red blood cells, white blood cells, 206 
neutrophils, haematocrit, as well as haemoglobin were found for all of the drugs (with the 207 
exception of alendronic acid).  Therefore, CERT may not be particularly discriminating for drug 208 
effects on those laboratory tests.   209 
In “hepatobiliary enzymes”, ALT and AST showed good PPV (92%, 87%) and specificity (83%, 210 
83%), suggesting potential utility in detecting hepatotoxicity signals. The trade-off is the lower 211 
sensitivity (59%, 32%), potentially missing some valid signals. For the “renal function and urine 212 
tests”, creatinine showed good PPV (80%) and specificity (93%) but very low sensitivity (11%). 213 
BUN had good PPV (77%) and sensitivity (62%). Many signals for increased potassium were 214 
detected which were not reported in UpToDate®.5  The lipid and metabolism, hormones and 215 
other panels also had high specificity (>87%) but low sensitivity (16-17%). PPV was also low, 216 
presumably because ADRs related to these abnormalities are rarer.  217 
Performance across different variations 218 
Among the four initial variations, Variations 1, 3 and 4 generally did not perform better than 219 
the original algorithm (Table 6, Figure 2).  Variation 2 had the best specificity (76.8%, Table 6).  220 
However, this was accompanied by a large drop in sensitivity (38.3%).  When we examined 221 
the evaluation metrics as a function of number of cases, we noted that sensitivity increased 222 
above 50% when there were 400 or more cases (Figure 1). Increasing the minimum number 223 
of cases from two to 400 cases for each drug-laboratory abnormality pair appears to better 224 
control the number of false negatives, as expected from increased power of a larger sample 225 
size. Hence, we performed a post-hoc analysis by imposing a threshold of 400 cases (Variation 226 
5). Variation 5, not surprisingly because of its post-hoc nature, gave the best overall 227 
performance (PPV 53.9%, sensitivity 67.2%, F-score 59.8%), and hereafter is referred to as 228 
CERT400.   229 
Negative controls   230 
We tested CERT on three negative controls: chlorpheniramine, metronidazole and risedronic 231 
acid.  These drugs have no signals in the reference standard that would be indicative of 232 
laboratory abnormalities. Yet, for all three drugs, CERT detected decreases in red blood cell, 233 
white blood cell, neutrophil, haematocrit, haemoglobin, and protein, as well as increases in 234 
platelets and alkaline phosphatase (ALP).  As noted above, most haematopoeisis tests 235 
returned positive results for all drugs, therefore these tests are of limited utility for ADR signal 236 
detection using CERT.   237 
DISCUSSION 238 
As a drug regulatory authority responsible for monitoring the post-market safety of drugs, 239 
HSA has been interested in supplementing SRS with other methodologies to strengthen the 240 
system for identifying drug safety signals. Knowledge of the full safety profile of a drug, 241 
particularly for rarer adverse reactions, only becomes available through post-marketing 242 
surveillance from drug usage in actual clinical practice across a broad population.6  With EMRs, 243 
new opportunities have arisen to mine these information-rich resources for safety signals. 244 
Here, we have shown that the CERT algorithm, which utilises laboratory test data in a 245 
temporal relationship with drug exposure, can be implemented on EMR data in a healthcare 246 
institution from another country with a different population.  We have examined the 247 
performance of CERT for 53 drugs, of which direct comparison could be performed for 6 drugs 248 
in both countries. We also investigated 5 variations of the original CERT algorithm, and 249 
identified two that improve specificity and/or sensitivity.  250 
The PPV of CERT was high for the liver enzymes ALT and AST and renal tests serum BUN and 251 
creatinine (92%, 87%, 77% and 80%, respectively), thus a positive signal from CERT is likely to 252 
signify hepatic and renal toxicity. However, the aminoglycosides gentamicin and amikacin, 253 
which are known to be nephrotoxic, did not show a positive signal with either increased 254 
creatinine or BUN. This could be a result of close monitoring of renal function and/or 255 
therapeutic drug monitoring by clinicians to prevent any acute renal injury, thereby 256 
dampening the incidence of a well-known signal. CERT did detect a signal of raised creatinine 257 
for other drugs with known nephrotoxic potential (e.g. hydrochlorothiazide, ranitidine, 258 
cefazolin), but sensitivity of the serum creatinine test was low (11%). However, sensitivity for 259 
BUN was much higher at 62%.   260 
CERT appears to be less discriminating for the hematopoiesis and coagulation panel, as nearly 261 
every drug had one or more signals in this panel. This may be more a reflection of the course 262 
of the disease or treatment. Similarly, the high number of false positives with potassium may 263 
be due to the high incidence of hyperkalaemia (up to 10%) in hospitalised patients, as many 264 
conditions can affect potassium levels (e.g. transcellular shifts, impaired excretion, or increase 265 
in potassium intake).5 Indeed, a major limitation of the CERT algorithm is the lack of 266 
adjustment for confounding factors.  The CLEAR algorithm7 , also developed by the Ajou 267 
University group, controls for confounder effects with the use of matched controls having the 268 
same admitting department and diagnosis but who had not taken the drug, but CLEAR is much 269 
more computationally intensive.  Another limitation is the lack of an actual gold standard for 270 
ADRs. Even though we created a reference standard using UpToDate 2015, we cannot confirm 271 
that the ADRs listed are indeed true ADRs. In addition, for chronic medications (e.g. 272 
simvastatin, enalapril), patients might already be taking them prior to admission. As such, the 273 
pre-exposure laboratory test results retrieved by CERT for these cases may not be true, 274 
potentially diluting any positive signals.  275 
In the original CERT algorithm, all tests in the pre- and post-drug exposure period were 276 
included.  However, it was often the case that many more tests were ordered during the post-277 
drug exposure period, which tends to inflate the chance finding of an abnormal result in the 278 
post-drug exposure period. By limiting the number of tests in the post-drug exposure period 279 
to two more than the number in the pre-drug exposure period (Variation 2), we observed an 280 
increase in the specificity of CERT from 65.4% to 76.8%.  The original CERT algorithm counted 281 
a drug-laboratory abnormality pair if there were at least two cases. We found that raising the 282 
minimum to 400 cases for each drug-laboratory abnormality pair (CERT400) helped to reduce 283 
the false negative rate, increasing the sensitivity from 54.1% to 67.2%. However, since the 284 
choice of 400 is based on results in these data, these estimates may be biased upwards. 285 
Although these performance metrics are not sufficiently high to solely rely on CERT400 for 286 
active surveillance, it promises to be a valuable addition to the toolkit for postmarket 287 
surveillance. A drug-laboratory abnormality pair identified by an automated CERT400 288 
algorithm could then be further evaluated by other methodologies such as text mining of 289 
discharge summaries8-10  to determine the validity of the signal. In the case of infrequently 290 
ordered laboratory tests, rarely used drugs, or newly approved drugs where usage has yet to 291 
pick up, the use of CERT400 may hinder detection of safety signals, since there may be 292 
insufficient cases to meet the minimum.  With the growth of electronic data in healthcare 293 
databases and linkages across multiple institutions, however, we anticipate that the rising 294 
volume of data will overcome the limitation of having this threshold of cases for evaluating 295 
the algorithm. 296 
Other groups have been investigating a variety of data mining methodologies to query health 297 
records for identification of ADRs based primarily on clinical features.11-16  One notable effort 298 
is the Sentinel Initiative funded by the United States Food and Drug Administration.  Specific 299 
queries of interest are submitted to the Sentinel coordinating center, which sends computer 300 
programs to data partners to extract and aggregate data on administrative and insurance 301 
claims data of over 180 million subjects.17  The Sentinel group successfully identified 302 
intussusception after rotavirus vaccination in infants13  and risk of coeliac disease in patients 303 
on long-term therapy with olmesartan18, 19 from algorithms applied to their extensive 304 
databases. The Observational Medical Outcomes Partnership investigated methods that 305 
relied primarily on diagnosis codes in administrative databases.11, 20, 21  Our dataset had 306 
limited structured diagnostic coding, which made it challenging for us to explore algorithms 307 
that rely on codes such as ICD-9.     308 
Methods using abnormal laboratory values for identifying ADRs have been investigated 309 
previously. In a study by Levy et al22 , automatic laboratory signals were generated when a 310 
specific laboratory value met a pre-defined criteria and tested on a prospective cohort of 192 311 
patients.  A list of cases was generated for further manual review. The false positive rate 312 
throughout the entire study period was 83%, which is a likely barrier to implementation. 313 
Ramirez et al implemented a prospective program based on automatic laboratory signals (ALS) 314 
for 54,525 hospitalisations in Spain.23  The algorithm flagged patients whose laboratory values 315 
met the criteria specified for six serious ADRs, but did not include a temporal relationship with 316 
drug intake, hence the cases needed to be manually reviewed to determine if the timing of 317 
drug intake could account for the abnormal laboratory values. The authors concluded that 318 
this was an intensive manual process requiring considerable effort.  319 
Liu et al3 aimed to have a more automated methodology that incorporated a temporal 320 
relationship with drug exposure. Abnormal laboratory results were correlated with specific 321 
drug administration by comparing the outcomes of drug-exposed and a matched unexposed 322 
group; higher thresholds for categorizing a laboratory result as abnormal were used and a 323 
minimum of 25 cases was required. When benchmarked with two reference datasets (the 324 
same 10 drugs evaluated by Yoon et al. or 9 other drugs), the reporting odds ratio (ROR) 325 
method performed best when applied to an EMR database containing four times more unique 326 
patients than the NUH database (PPV 77% and 58% respectively, sensitivity 61% and 67%, 327 
respectively). 328 
In summary, we have demonstrated the transferability of the CERT algorithm to a health care 329 
institution of another country. We have developed a reference standard of drug-laboratory 330 
abnormalities for 53 drugs based on the 2015 version of UpToDate® to evaluate CERT on our 331 
data, and which can also be used to benchmark other published algorithms. CERT400, a 332 
modification of CERT which only accepts results generated from more than 400 drug-333 
laboratory abnormality cases, gave the best overall performance with a PPV of 53.9% and 334 
sensitivity of 67.2% (F-score 59.8%). High PPV for increased AST and ALT enzyme levels, BUN 335 
and serum creatinine suggests that CERT would be particularly useful for identifying drug-336 
induced hepatic and renal toxicities.  The ability of CERT400 to sift through a large volume of 337 
laboratory tests obtained before and after drug exposure and identify potential signals with 338 
reasonable positive predictive value and sensitivity indicates that it will be a useful tool to add 339 
to a pharmacovigilance programme.   340 
  341 
Tables and Figures 342 
 343 
Table 1: Database size and number of patient visits used for CERT comparison between Ajou 344 
University Hospital and NUH  345 
 
Ajou University Hospital NUH 
Number of patient visits* 1,011,055 272,328 
Drug Number of Visits 
Ciprofloxacin 16,706 17,576 
Clopidogrel 19,188 28,672 
Levofloxacin    9,059   4,673 
Ranitidine 68,995   7,474 
Rosuvastatin    4,811   2,252 
Valproic acid 11,523   4,300 
 346 
*Number of hospitalizations during which the patient received at least one dispensing of the drug. 347 
 348 
  349 
Table 2: Number of patient visits for 47 drugs used in Round 2  350 
Drug 
No. of patient 
visits 
Drug 
No. of patient 
visits 
Aciclovir 5,353 Ezetimibe 2,809 
Alendronic acid 2,009 Famotidine 23,590 
Allopurinol 8,694 Fenofibrate 6,552 
Amikacin 1,629 Fluconazole 3,566 
Amoxicillin-Clavulanic Acid 116,511 Gentamicin 13,512 
Ampicillin 4,850 Gliclazide 8,622 
Azithromycin 5,812 Hydrochlorothiazide 6,811 
Carbamazepine 1,373 Imipenem-cilastatin 3,509 
Carvedilol 40,013 Isoniazid 1,610 
Cefazolin 26,750 Itraconazole 629 
Ceftazidime 7,228 Levetiracetam 7,955 
Ceftriaxone 74,834 Losartan 19,158 
Celecoxib 3,266 Meropenem 26,273 
Chlorpheniramine 26,790 Metformin 55,881 
Clarithromycin 17,382 Metronidazole 22,212 
Clindamycin 3,869 Omeprazole 163,999 
Cloxacillin 6,505 Phenytoin 5,136 
Cotrimoxazole 14,969 Piperacillin-Tazobactam 14,843 
Digoxin 17,338 Pyrazinamide 1,061 
Domperidone 10,004 Rifampicin 1,758 
Doxycycline 1,813 Risedronic acid 1,551 
Enalapril 57,621 Simvastatin 81,590 
Entecavir 1,368 Vancomycin 34,028 
Ethambutol 1,328   
 351 
  352 
Table 3: Variations of the original CERT algorithm 353 
Algorithm 
Input (laboratory 
test results) 
Observation 
period after drug 
exposure 
Minimum 
no. cases 
required Statistical test 
Original Extreme values Till discharge 2 
Paired t-test & 
McNemar's test 
Variation 1 Extreme values 12 days 2 
Paired t-test & 
McNemar’s test 
Variation 2 Extreme values 
(n+2) laboratory 
test results 
2 
Paired t-test & 
McNemar’s test 
Variation 3 
Average of the two 
most extreme 
values 
Till discharge 2 
Paired t-test & 
McNemar’s test 
Variation 4 Extreme values Till discharge 2 
Paired t-test 
&Wilcoxon’s signed-rank 
test 
Variation 5 
(CERT400) 
Extreme values Till discharge 400 
Paired t-test & 
McNemar’s test 
Variation 1: Limit the unit of observation to 12 days after drug exposure, which is the mean (7.1 days) 
plus 2 times the standard deviation (2.6 days) of the time from drug administration to the time the 
extreme post-drug laboratory value was taken for all true positive cases. 
Variation 2: Limit the unit of observation to a maximum of (n+2) laboratory test results for each 
encounter, where n is the number of laboratory tests before the drug was started.   
Variation 3: Take the mean of the two most extreme values for both the pre- and post-drug periods, 
to minimize the possibility that a single extreme value, such as one caused by measurement error, 
would unduly influence the result.  
Variation 4: Use the non-parametric Wilcoxon’s signed-rank test to replace the McNemar’s test. 
Variation 5 (Post-hoc variation): Impose a minimum of 400 cases for each drug-laboratory test pair 
based on results shown in Figure 1. 
 354 
 355 
 356 
  357 
 358 
Table 4A: Performance Metrics of CERT: Comparison between NUH and Ajou* 359 
 PPV (%) NPV (%) Sensitivity  
(%) 
Specificity  
(%) 
F-
score 
(%) 
Avg. No. of 
signals 
detected per 
drug 
NUH 57.0 58.1 48.6 63.9    52.5 113/6 = 18.8 
Ajou University 
Hospital 
57.4 66.6 69.4 52.1 62.8 155/6 = 25.8 
Average performance for the 6 drugs from original paper 360 
*Results are benchmarked according to the 2010 Version of UpToDate used in original CERT paper. Six 361 
drugs included in the comparison are ciprofloxacin, clopidogrel, levofloxacin, ranitidine, rosuvastatin, 362 
and valproic acid  363 
  364 
 365 
Table 4B: Performance Metrics of CERT:  Comparison between Rounds 1 and 2 based on NUH EMR 366 
data* 367 
 No. of 
evaluated 
drugs  
PPV  
(%) 
NPV  
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
F-score 
(%) 
Avg. No. 
of signals 
detected 
per drug 
 Round 1  6 63.4 55.1 49.8 66.8 55.8 
113/6 = 
18.8 
 Round 2 47 45.6 70.6 55.5 64.4 50.1 
885/47 = 
18.8 
Total 53 47.6 68.9 54.8 64.6 51.0 
998/53 = 
18.8 
*Results are benchmarked according to 2015 Version of UpToDate 368 
 369 
 370 
 371 
 372 
  373 
Table 5: Performance Metrics of CERT algorithm for 53 drugs – Comparison across Laboratory 374 
Panels* 375 
A) Analysis according to the original CERT algorithm for laboratory panels or 376 
selected tests 377 
Laboratory 
Panel or Test 
Avg. no. of 
cases 
No. of 
positive 
Signals 
PPV NPV Sensitivity Specificity F-score 
(%) (%) (%) (%) (%) 
Hemato-
poiesis and 
coagulation 
2634 600 44.7 71.7 67.3 49.8 53.7 
Hepatobiliary 
enzymes 
1507 228 63.6 31.5 59.7 35.2 61.6 
    AST 1532 15 86.7 26.3 31.7 83.3 46.4 
    ALT 1533 26 92.3 37.0 58.5 83.3 71.6 
Renal function 
and urine 
tests 
3867 75 61.3 35.7 46.0 50.8 52.6 
    BUN 3835 30 76.7 39.1 62.2 56.3 68.7 
    CRE 3848 5 80.0 29.2 10.5 93.3 18.6 
    K 3917 40 47.5 53.8 76 25 58.5 
Lipids and 
metabolism 
80 32 25.0 82.8 16.7 88.9 20.0 
Hormones 104 14 14.3 89.1 16.7 87.2 15.4 
Others 1158 49 34.7 71.1 15.5 87.7 21.4 
 378 
  379 
B) Analysis according to the CERT400 algorithm for laboratory panels or 380 
selected tests 381 
Laboratory 
Panel or Test 
Avg. no. of 
cases 
No. of 
positive 
Signals 
PPV NPV Sensitivity Specificity F-score 
(%) (%) (%) (%) (%) 
Hemato-
poiesis and 
coagulation 
3663 512 48.8 64.9 74.9 37.2 59.1 
Hepatobiliary 
enzymes 
2255 177 64.4 33.9 73.5 25.0 68.7 
    AST 2042 12 91.7 26.9 36.7 87.5 52.4 
    ALT 2000 23 91.3 37.5 67.7 75.0 77.8 
Renal function 
and urine 
tests 
4408 69 62.3 36.2 49.4 49.0 55.1 
    BUN 4372 27 74.1 36.8 62.5 50.0 67.8 
    CRE 4386 5 80.0 29.3 12.1 92.3 21.1 
    K 4466 37 51.4 66.7 86.4 25 64.4 
Lipids and 
metabolism 
639 5 40 40 40 40 40 
Hormones 567 1 0 100 Not valid 50 Not valid 
Others 2682 45 33.3 73.6 34.1 73.0 33.7 
*Results are benchmarked according to 2015 Version of UpToDate 382 
  383 
  384 
Table 6: Performance Metrics for the Original CERT Algorithm and 5 Variations* 385 
Variation No. of 
cases 
(Avg) 
No. of 
positive 
Signals 
PPV 
(%) 
NPV 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
F-score 
(%) 
 
Original 1899 998 50.3 67.2 54.1 65.4 52.1 
Variation 1 1853 761 50.6 64.5 40.3 74.1 44.9 
Variation 2 1899 707 51.6 64.6 38.3 76.8 44.0 
Variation 3 1833 905 49.1 65.6 48.4 68.2 48.7 
Variation 4  1898 1385 44.8 64.4 66.9 45.0 53.7 
Variation 5 
(CERT400) 
2969 792 53.9 53.5 67.2 42.3 59.8 
*Results are benchmarked according to 2015 Version of UpToDate for 53 drugs and 44 laboratory 386 
abnormalities 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
Figure 1: CERT Algorithm: Dependence of PPV, Sensitivity and F-score on Number of Cases* 406 
 407 
*53 drugs, 44 laboratory abnormalities 408 
  409 
Figure 2: Performance metrics and 95% confidence interval based on random effects meta-analysis 410 
for all the 53 drugs. 411 
  412 
  413 
Supplementary tables: (Recommended to put as additional supporting information online) 414 
Table S1: List of the 44 selected laboratory test abnormalities according to the laboratory panels. 415 
Hematopoiesis and coagulation 
 
Renal function and urine tests 
Activated partial thromboplastin 
time  
Increased 
 
Blood urea nitrogen  Increased 
  Decreased 
 
Creatinine Increased 
Basophil Decreased 
 
Potassium  Increased 
Eosinophil  Increased 
 
Lipids and metabolism 
  Decreased 
 
Cholesterol  Increased 
Fibrinogen Decreased 
 
Glucose Increased 
Hematocrit Decreased 
 
  Decreased 
Hemoglobin  Increased 
 
LDL cholesterol Increased 
  Decreased 
 
Triglyceride  Increased 
Lymphocyte  Increased 
 
Hormones 
Neutrophil Decreased 
 
Free thyroxine  Increased 
Platelet  Increased 
 
  Decreased 
  Decreased 
 
Others 
Prothrombin time  Increased 
 
Ammonemia  Increased 
  Decreased 
 
Amylase  Increased 
Red blood cell Decreased 
 
Creatine kinase  Increased 
Reticulocyte  Increased 
 
Lactate dehydrogenase  Increased 
  Decreased 
 
Lipase  Increased 
White blood cell  Increased 
 
Sodium Decreased 
  Decreased 
 
Uric acid  Increased 
Hepatobiliary enzymes 
   
Alanine transaminase  Increased 
   
Alkaline phosphatase  Increased 
   
Aspartate transaminase  Increased 
   
Direct bilirubin  Increased 
   
Gamma-glutamyl transpeptidase  Increased 
   
Protein Decreased 
   
Total bilirubin  Increased 
   
 416 
 417 
  418 
Table S2 (a): Evaluation metrics PPV, NPV, sensitivity (sens), specificity (spec) and F-score. 419 
Algorithm Result 
2010/2015 Version of UpToDate 
 
Present Absent 
Positive 𝑇𝑃 𝐹𝑃 𝑃𝑃𝑉 =  
𝑇𝑃
𝑇𝑃 + 𝐹𝑃
 
Negative 𝐹𝑁 𝑇𝑁 𝑁𝑃𝑉 =  
𝑇𝑁
𝐹𝑁 + 𝑇𝑁
 
 𝑠𝑒𝑛𝑠 =  
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
 𝑠𝑝𝑒𝑐 =  
𝑇𝑁
𝐹𝑃 + 𝑇𝑁
 
  
𝐹 − 𝑠𝑐𝑜𝑟𝑒
=
2 × 𝑃𝑃𝑉 𝑥 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
𝑃𝑃𝑉 + 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
 
 
 420 
Table S2 (b): Example to show the performance metrics for ALT laboratory test abnormality on the 421 
53 drugs we tested. 422 
Algorithm Result 
(for ALT) 
2015 Version of UpToDate (for ALT) 
 
Present Absent 
Positive 24 2 𝑃𝑃𝑉 =  
24
26
= 92% 
Negative 17 10 𝑁𝑃𝑉 =  
10
27
= 37% 
 𝑠𝑒𝑛𝑠 =  
24
41
= 59% 𝑠𝑝𝑒𝑐 =  
10
12
= 83% 
𝐹 − 𝑠𝑐𝑜𝑟𝑒 = 72% 
 423 
  424 
Table S3:  Reference Standard of drug ADRs developed from UpToDate® 2015* 425 
 426 
 427 
*This table is uploaded separately online as well. 428 
  429 
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